Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets DOI
Yang Liu,

Yawen Hao,

Joost Boeckmans

et al.

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 243, P. 108353 - 108353

Published: Feb. 2, 2023

Language: Английский

Hepatic inflammatory responses in liver fibrosis DOI
Linda Hammerich, Frank Tacke

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(10), P. 633 - 646

Published: July 3, 2023

Language: Английский

Citations

327

Cirrhosis-associated immune dysfunction DOI
Agustı́n Albillos, Rosa Martín‐Mateos, Van der Merwe

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 19(2), P. 112 - 134

Published: Oct. 26, 2021

Language: Английский

Citations

260

Animal models for liver disease – A practical approach for translational research DOI Open Access
Yulia A. Nevzorova, Zoé Boyer-Díaz, Francisco Javier Cubero

et al.

Journal of Hepatology, Journal Year: 2020, Volume and Issue: 73(2), P. 423 - 440

Published: April 21, 2020

Language: Английский

Citations

194

Alcohol-associated liver disease DOI Creative Commons
Bryan Mackowiak, Yaojie Fu, Luca Maccioni

et al.

Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 134(3)

Published: Feb. 1, 2024

Alcohol-associated liver disease (ALD) is a major cause of chronic worldwide, and comprises spectrum several different disorders, including simple steatosis, steatohepatitis, cirrhosis, superimposed hepatocellular carcinoma. Although tremendous progress has been made in the field ALD over last 20 years, pathogenesis remains obscure, there are currently no FDA-approved drugs for treatment ALD. In this Review, we discuss new insights into therapeutic targets ALD, utilizing study multiomics other cutting-edge approaches. The potential translation these studies clinical practice therapy deliberated. We also preclinical models interplay metabolic dysfunction, alcohol-associated cancer, heterogeneity some translational research prospects

Language: Английский

Citations

117

Macrophage plasticity: signaling pathways, tissue repair, and regeneration DOI Creative Commons
Lingfeng Yan, Jue Wang,

Xin Cai

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(8)

Published: Aug. 1, 2024

Abstract Macrophages are versatile immune cells with remarkable plasticity, enabling them to adapt diverse tissue microenvironments and perform various functions. Traditionally categorized into classically activated (M1) alternatively (M2) phenotypes, recent advances have revealed a spectrum of macrophage activation states that extend beyond this dichotomy. The complex interplay signaling pathways, transcriptional regulators, epigenetic modifications orchestrates polarization, allowing respond stimuli dynamically. Here, we provide comprehensive overview the cascades governing focusing on roles Toll‐like receptors, signal transducer activator transcription proteins, nuclear microRNAs. We also discuss emerging concepts metabolic reprogramming trained immunity, contributing their functional adaptability. Macrophage plasticity plays pivotal role in repair regeneration, macrophages coordinating inflammation, angiogenesis, matrix remodeling restore homeostasis. By harnessing potential novel therapeutic strategies targeting polarization could be developed for diseases, including chronic wounds, fibrotic disorders, inflammatory conditions. Ultimately, deeper understanding molecular mechanisms underpinning will pave way innovative regenerative medicine engineering approaches.

Language: Английский

Citations

36

Cell senescence in liver diseases: pathological mechanism and theranostic opportunity DOI
David Sanfeliu-Redondo, Albert Gibert‐Ramos, Jordi Gracia‐Sancho

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(7), P. 477 - 492

Published: March 14, 2024

Language: Английский

Citations

24

Immunopathobiology and therapeutic targets related to cytokines in liver diseases DOI Creative Commons
Yong He, Seonghwan Hwang,

Yeni Ait Ahmed

et al.

Cellular and Molecular Immunology, Journal Year: 2020, Volume and Issue: 18(1), P. 18 - 37

Published: Nov. 17, 2020

Chronic liver injury with any etiology can progress to fibrosis and the end-stage diseases cirrhosis hepatocellular carcinoma. The progression of disease is controlled by a variety factors, including injury, inflammatory cells, mediators, cytokines, gut microbiome. In current review, we discuss recent data on large number cytokines that play important roles in regulating inflammation, fibrosis, regeneration, focus interferons T helper (Th) 1, Th2, Th9, Th17, interleukin (IL)-1 family, IL-6 IL-20 family cytokines. Hepatocytes also produce certain (such as IL-7, IL-11, IL-33), functions these are briefly summarized. Several have great therapeutic potential, some currently being tested targets clinical trials for treatment diseases, which described.

Language: Английский

Citations

109

Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure DOI Creative Commons
Mireia Casulleras, Ingrid W. Zhang, Cristina López‐Vicario

et al.

Cells, Journal Year: 2020, Volume and Issue: 9(12), P. 2632 - 2632

Published: Dec. 8, 2020

Acute-on-chronic liver failure (ACLF) is a complex syndrome that develops in patients with cirrhosis and characterized by acute decompensation, organ failure(s) high short-term mortality. ACLF frequently occurs close temporal relationship to precipitating event, such as alcoholic, drug-induced or viral hepatitis bacterial infection and, cases without events, probably related intestinal translocation of products. Dysbalanced immune function central its pathogenesis outcome an initial excessive systemic inflammatory response drives This hyperinflammatory state ultimately impairs the host defensive mechanisms cells, rendering immunocompromised more vulnerable secondary infections, therefore higher dysfunction In this review, we describe prevailing characteristics acutely decompensated developing ACLF, special emphasis on cells innate system (i.e., monocytes neutrophils), their triggers (pathogen- damage-associated molecular patterns [PAMPs DAMPs]), effector molecules (cytokines, chemokines, growth factors bioactive lipid mediators) consequences tissue immunopathology. addition, review includes chapter discussing new emerging therapies based modulation leukocyte administration pleiotropic proteins albumin, Toll-like receptor 4 antagonists, interleukin-22 stem cell therapy. Finally, importance finding appropriate intervention reduces inflammation inducing immunosuppression highlighted one main therapeutic challenges cirrhosis.

Language: Английский

Citations

104

Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications DOI
Csaba Mátyás,

György Haskó,

Lucas Liaudet

et al.

Nature Reviews Cardiology, Journal Year: 2020, Volume and Issue: 18(2), P. 117 - 135

Published: Sept. 30, 2020

Language: Английский

Citations

101

Acute-on-chronic liver failure: A distinct clinical syndrome DOI
Richard Moreau, Bin Gao, Mária Papp

et al.

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 75, P. S27 - S35

Published: May 23, 2021

Language: Английский

Citations

97